AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Expanding Immunology Portfolio
ABBV sits 20% above its 52-week low of $181.73.
Summary
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash, bolstering its immunology and respiratory portfolios with clinical-stage assets.
Key Events · M&A and Partnerships · ABBV
-
Acquisition Agreement
AbbVie will acquire Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction, paying $135.11 per share. The transaction is expected to close in the third quarter of 2026.
-
Strategic Portfolio Expansion
The acquisition adds a diverse pipeline of immunology assets, including zumilokibart (atopic dermatitis) and APG273 (asthma), strengthening AbbVie's presence in dermatology and accelerating its entry into the respiratory space.
-
Financial Impact
The transaction is expected to negatively impact adjusted diluted EPS by approximately $0.14 in 2026 (partial year) and $0.46 in 2027, with accretion projected to begin in 2032.
Analysis · ABBV · Life Sciences
This acquisition significantly strengthens AbbVie's immunology pipeline by adding late-stage assets like zumilokibart for atopic dermatitis and APG273 for asthma. While the deal is expected to dilute adjusted EPS until 2032, it provides long-term growth potential in key therapeutic areas, leveraging AbbVie's existing expertise and infrastructure.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.1% of the 284 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABBV was trading at $218.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $382.5B. The 52-week trading range was $181.73 to $244.81. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.